A 40 year old man had an episode of severe pulmonary oedema at 4000-5000 m during the ascent of the Margherita peak (5109 m) (3310 im), on the second, and to the Kiondo hut (4100 m) on the third. The next day he walked down to the Green Lake (3900 m) and up again to the Gray Lake (4200 m), at the edge of the West Stanley Glacier where the party set up a base camp. Since his arrival in Kigali he had been taking longacting acetazolamide (500 mg per day). On the third day of the march, he had a headache, lost his appetite, and slept poorly. Seven days after his arrival in Africa he rested but was sick and drowsy with a headache, and ate little. He started to take dexamethasone (initial dose 8 mg then 4 mg every 6 hours). Next morning, after he had taken a total dose of 20 mg of dexamethasone, he was much improved though still anorectic. Soon after starting to lead the ice climb to the main summit he became very short of breath and coughed up blood tinged sputum. Close to the summit (5000 m) intense lassitude, dyspnoea, and a thick mist forced him to descend. Back at the base camp in the evening he was exhausted, very short of breath at the slightest effort, had an audible gurgling in his chest, blood stained sputum, and was suffocating in the supine position. He then realised he had high altitude pulmonary oedema and decided to try to get to a lower altitude while he was able to walk. Together with a companion and a porter, he reached Mutuanga the next day in the evening. For 48 hours he remained orthopnoeic and dyspnoeic on exertion or when drinking a beer. A physical examination performed by a local physician disclosed crepitant inspiratory rales over the lower half of both lungs that progressively cleared in 48 hours. The nearest x ray facility was two days drive away. Back in Brussels, physical examination, standard blood tests, electrocardiogram, chest x ray, and echocardiographic examination were normal.
High altitude pulmonary oedema is an uncommon but dangerous complication of acute mountain sickness that occurs in individuals rapidly ascending to > 3000 m. High altitude pulmonary oedema is believed to be caused by excessive and uneven pulmonary vasoconstriction in response to hypoxia.' Whether susceptibility to high altitude pulmonary oedema can be reliably detected by testing pulmonary vascular reactivity to hypoxia at lower altitudes remains uncertain.'"3 A low rate of ascent and limited exertion usually prevent the development of acute mountain sickness and its complications. This is not always practical, especially during mountain rescues and military activities, nor is it an acceptable strategy when recreation time is limited. Many mountaineers attempt prophylaxis with pharmacological agents. Only acetazolamide and dexamethasone are known to be effective. 4 We report a man with normal hypoxic pul- recently suggested that dexamethasone might even be effective in the treatment of severe acute mountain sickness.4 There are no data on the effects of combined acetazolamide and dexamethasone.4 In our patient the addition of dexamethasone to acetazolamide resulted in such a subjective improvement that he undertook an ice climb, but symptoms of a lifethreatening pulmonary oedema then developed. Levine et al showed that dexamethasone improved the symptoms of acute mountain sickness in six individuals exposed to a simulated altitude of 3700 m in a hypobaric chamber but did not prevent the development of objective physiological abnormalities related to exposure to high altitude. '4 Neither acetazolamide nor dexamethasone have ever been shown to improve high altitude pulmonary oedema."4 Drug treatment should never be used to permit further ascent by a patient with acute mountain sickness.
